Why Nurix Therapeutics (NRIX) moved after its latest capital move

Nurix Therapeutics (NRIX) recently expanded its equity distribution agreement, giving it room to sell up to $413.65 million of common stock through Piper Sandler. This step directly affects its capital-raising flexibility and potential dilution.

The capital plan arrives after a tougher few months for the share price, with a 30 day share price return showing an 8% decline and a 90 day share price return showing a 20.72% decline, even though the 1 year total shareholder return is 14.05% and the 3 year total shareholder return is 68.30%. Recent weakness therefore contrasts with stronger longer term investor outcomes.

If you are looking beyond a single biotech name, this could be a good moment to see what else is on the move with our screener of 32 healthcare AI stocks.

With Nurix shares down over the past quarter but still ahead on a 1 and 3 year view, and with new equity capacity in place, is the current price a reset that leaves upside on the table, or is the market already factoring in future growth?

Preferred Price-to-Sales of 19x: Is it justified?

Nurix trades on a P/S of 19x, which is higher than both its biotech peers and our fair ratio estimate, so the current share price bakes in a lot of revenue optimism.

The P/S multiple compares the company’s market value to its annual revenue and is often used for early stage or unprofitable biotech names where earnings are still negative. In Nurix’s case, revenue is forecast to grow 37.9% per year, yet analysts also expect the company to remain unprofitable over the next 3 years, so investors are effectively paying up today for the possibility that this revenue line eventually supports a sustainable business model.

Compared with the US Biotechs industry average P/S of 12x and a peer group average of 14.9x, Nurix’s 19x stands out as expensive. Our fair P/S ratio estimate of 0.2x is also far below the current level, which points to a wide gap between what the market is currently willing to pay and where the ratio could move if expectations reset closer to that fair level.

Result: Price-to-Sales of 19x (OVERVALUED)

However, this story also leans heavily on future execution, with ongoing losses of $264.457 million and a relatively high P/S of 19x, which raises clear downside risk.

Next Steps

If this mix of pressure and potential feels finely balanced, act while the data is fresh, weigh it yourself, and check out 1 key reward and 2 important warning signs to see the full picture.

Looking for more investment ideas?

Do not stop with one company. Broaden your watchlist now so you can compare quality, risk and income potential across a wider set of opportunities.

• Hunt for potential mispricings with our screener of 46 high quality undervalued stocks that line up strong fundamentals with appealing valuations.
• Prioritise resilience by scanning 63 resilient stocks with low risk scores that score well on financial strength and business stability.
• Target dependable income by reviewing 14 dividend fortresses that aim to pair higher yields with sturdier balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.